Clinical trial · Observational
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in the Treatment of Microsatellite Stable Advanced Colorectal Cancer
NCT06682247CI-TRIAL-00082461not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- chidamide + PD-1/PD-L1 inhibitors +Bevacizumab or tyrosine kinase inhibitors
- interventionNames
- Drug: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Primary outcomes (1)
- measure
- Progression-free survival(PFS)
- timeFrame
- 2 years
Secondary outcomes (4)
- measure
- Objective Response Rate（ORR）
- timeFrame
- 2 years
- measure
- Clinical Benefit Rate (CBR)
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged≥18 years 2. Histology-confirmed metastatic CRC (mCRC); 3. ECOG 0\~2 4. At least one efficacy evaluation 5. Life expectancy of at least 3 months. Exclusion Criteria: 1. Lack of follow-up data. 2. Chidamide stopped after less than two cycles. 3. Serious comorbidities that interfere with the efficacy or safety analysis
References
Publications (0)
Data not yet available
No reference posted for this study.